Recarbrio Interactions
There are 37 drugs known to interact with Recarbrio (cilastatin/imipenem/relebactam), along with 6 disease interactions, and 1 alcohol/food interaction. Of the total drug interactions, 14 are major, 21 are moderate, and 2 are minor.
- View all 37 medications that may interact with Recarbrio
- View Recarbrio alcohol/food interactions (1)
- View Recarbrio disease interactions (6)
Most frequently checked interactions
View interaction reports for Recarbrio (cilastatin / imipenem / relebactam) and the medicines listed below.
- albuterol
- alprazolam
- Amitiza (lubiprostone)
- amlodipine
- amoxicillin
- amoxicillin / clavulanate
- azathioprine
- azithromycin
- Bactroban Nasal (mupirocin topical)
- benzonatate
- Breo Ellipta (fluticasone / vilanterol)
- Brovana (arformoterol)
- clopidogrel
- dexamethasone
- diazepam
- dicyclomine
- Diflucan (fluconazole)
- diflunisal
- duloxetine
- DuoNeb (albuterol / ipratropium)
- Entyvio (vedolizumab)
- famotidine
- Flagyl (metronidazole)
- fluticasone topical
- Fosamax (alendronate)
- furosemide
- gabapentin
- guaifenesin
- hydroxychloroquine
- magnesium oxide
Recarbrio alcohol/food interactions
There is 1 alcohol/food interaction with Recarbrio (cilastatin / imipenem / relebactam).
Recarbrio disease interactions
There are 6 disease interactions with Recarbrio (cilastatin / imipenem / relebactam) which include:
More about Recarbrio (cilastatin / imipenem / relebactam)
- Recarbrio consumer information
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: carbapenems/beta-lactamase inhibitors
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.